Search for: "Novartis Pharmaceuticals Inc" Results 241 - 260 of 393
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
8 Sep 2011, 11:04 am by Tom Lamb
., Inc.; ACTONEL (risedronate sodium) tablets, ATELVIA (risedronate sodium) delayed release tablets, and ACTONEL WITH CALCIUM (Copackaged) (risedronate sodium with calcium carbonate) tablets, Warner Chilcott, LLC; BONIVA (ibandronate sodium) tablets and injection, Roche Therapeutics, Inc.; RECLAST (zoledronic acid) injection, Novartis Pharmaceuticals Corporation; and, the generic equivalents for these products, if any. [read post]
8 May 2009, 8:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs)   General Alicia Greenidge to step down as Director of IFPMA (Intellectual Property Watch) Flu crisis could lead to compulsory licences (Managing… [read post]
3 Mar 2016, 5:19 am
Novartis Pharmaceuticals Corp., 247 P.3d 244, 257 (Mont. 2010); Downing v. [read post]
27 May 2010, 3:40 pm by Bexis
Merrell Dow Pharmaceuticals, Inc., 791 F. [read post]
21 Feb 2013, 3:45 pm
Arnold J set out the law on obviousness by reference to the restatement of the Windsurfing test in Pozzoli v BDMA SA [2007] EWCA Civ 588 and by reference to the consideration of that restated test in MedImmune Ltd v Novartis Pharmaceuticals Ltd [2012] EWCA Civ 1234. [read post]
20 Mar 2009, 2:05 am
Novartis Pharmaceuticals Corp., 283 F.3d 254, 272 n.11 (5th Cir. 2002); Williams v. [read post]
27 Dec 2007, 7:09 am
Novartis Pharmaceuticals Corp., 2007 WL 1521138 (D.N.J. [read post]
26 Jun 2015, 12:30 am
 Actually, Mr Justice Arnold had himself moved away from the idea already - he distinguished his decision in the later case of Idenix Pharmaceutical, Inc v Gilead Sciences, Inc (reported by IPKat here) in which he declined to construe a claim narrowly on the basis of the prosecution history.This did not however have any effect on the outcome - Floyd LJ otherwise endorsed Arnold J's application of the Protocol questions to likewise find that there was no direct… [read post]
16 Nov 2007, 4:00 am
: (LawFont),BrazilBrazil pays the price for compulsory licensing: (IAM), (Generic Pharmaceuticals & IP), CanadaThe Chronicle reports that Honourable Mr. [read post]
2 Nov 2007, 11:00 pm
: (PLI), (PatentDocs), (Patent Baristas), (Patently'O), Vonage settles patent dispure with Verizon: (IP Law360), Celgene and Novartis file extended release Ritalin suit: (IP Law360), T-Mobile USA is the latest to settle charges that it infringed technology for computerized sales methods held by patent-holding company Orion IP LLC: (IP Law360),Bayer beats Dr Reddy's on Avelox (moxifloxacin): (OrangeBookBlog), (Generic Pharmaceuticals), Martek obtains permanent injunction… [read post]
24 Aug 2011, 12:33 am by Marie Louise
Novartis (IPBiz) Simcor (Niacin, Simvastatin) – US: Abbott Laboratories files patent infringement complaint against Teva in response to Para IV challenge (Patent Docs) Vanos (Fluocinonide) – US: Medicis and Nycomed settle Vanos patent dispute (Patent Docs) Viagra (Sildenafil) – US: Pfizer’s patent on Viagra upheld by the EDVA: Pfizer v Teva (Rocket Docket IP Blog) (Patent Docs) (The IP Factor) [read post]
11 Jan 2008, 9:00 am
: (Biotech Weblog),Immunomedics obtains antibody patent: (SmartBrief),Cyplasin Biomedical obtains US patent for protein based cancer treatment: (Patent Docs)Argatroban - Encysive Pharmaceuticals Inc., GlaxoSmithKline and Mitsubishi Chemical Corp. file patent infringement lawsuit to stop Barr Laboratories from producing a generic version of the anti-blood clotting drug: (IP Law360), Biaxin (Clarithromycin) - Court holds in Abbott Labs v… [read post]
2 Apr 2013, 10:33 am by Anubha Sinha
George Yu, an experienced patent litigation lawyer at Schiff Hardin LLP on the legality of reverse payment settlements in the pharmaceutical sector- a strategy wherein a patent holder pays a generic pharmaceutical manufacturer to delay or withdraw any challenges to patent validity. [read post]
22 Jan 2024, 1:16 pm by Dennis Crouch
Novartis Pharmaceuticals Corporation (Amicus Curiae): Jane M. [read post]